Free Trial

Apollomics (APLM) Competitors

Apollomics logo
$6.23 +0.08 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$6.29 +0.06 (+0.96%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APLM vs. ENLV, SCYX, PMN, RANI, MIRA, CLSD, NNVC, FBLG, NRSN, and QTTB

Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Enlivex Therapeutics (ENLV), SCYNEXIS (SCYX), Promis Neurosciences (PMN), Rani Therapeutics (RANI), MIRA Pharmaceuticals (MIRA), Clearside Biomedical (CLSD), NanoViricides (NNVC), FibroBiologics (FBLG), NeuroSense Therapeutics (NRSN), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.

Apollomics vs. Its Competitors

Enlivex Therapeutics (NASDAQ:ENLV) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Enlivex Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 791.27%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Apollomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Apollomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enlivex Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.89 beat Enlivex Therapeutics' score of 0.63 indicating that Apollomics is being referred to more favorably in the news media.

Company Overall Sentiment
Enlivex Therapeutics Positive
Apollomics Very Positive

Apollomics' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A -57.67% -50.52%
Apollomics N/A N/A N/A

Enlivex Therapeutics has higher earnings, but lower revenue than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.70
Apollomics$1.49M4.60-$53.86MN/AN/A

Summary

Enlivex Therapeutics beats Apollomics on 7 of the 13 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLM vs. The Competition

MetricApollomicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.85M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A21.1828.1120.03
Price / Sales4.60337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book1.398.368.655.90
Net Income-$53.86M-$55.19M$3.25B$258.66M
7 Day Performance0.32%5.89%4.20%2.23%
1 Month Performance-1.11%17.63%10.83%12.77%
1 Year Performance-69.65%5.10%34.67%19.36%

Apollomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLM
Apollomics
1.0438 of 5 stars
$6.23
+1.3%
N/A-69.3%$6.85M$1.49M0.0045Positive News
Gap Up
ENLV
Enlivex Therapeutics
2.8112 of 5 stars
$1.19
+0.1%
$10.00
+739.6%
-19.6%$28.74MN/A-1.8470News Coverage
Analyst Forecast
Gap Up
SCYX
SCYNEXIS
0.9054 of 5 stars
$0.72
+0.9%
N/A-63.5%$28.02M$3.75M-1.2860Positive News
PMN
Promis Neurosciences
2.9746 of 5 stars
$0.84
-24.7%
$4.33
+414.0%
-56.9%$27.72MN/A-16.965News Coverage
Analyst Revision
High Trading Volume
RANI
Rani Therapeutics
2.3416 of 5 stars
$0.44
+4.3%
$7.33
+1,574.3%
-82.4%$27.69M$1.03M-0.44110Gap Up
MIRA
MIRA Pharmaceuticals
2.5884 of 5 stars
$1.66
-1.2%
$14.00
+743.4%
-26.3%$27.66MN/A-3.212
CLSD
Clearside Biomedical
2.0571 of 5 stars
$0.35
+2.1%
$4.20
+1,113.9%
-53.1%$27.28M$3.76M-0.8630High Trading Volume
NNVC
NanoViricides
0.354 of 5 stars
$1.69
-0.3%
N/A-31.3%$27.08MN/A-2.3420
FBLG
FibroBiologics
3.8153 of 5 stars
$0.66
-0.5%
$13.00
+1,857.8%
-86.2%$26.35MN/A-3.1610Positive News
Gap Up
NRSN
NeuroSense Therapeutics
2.7267 of 5 stars
$1.92
-0.6%
$14.00
+629.5%
+144.9%$26.18MN/A-3.5510
QTTB
Q32 Bio
2.5162 of 5 stars
$2.14
-1.9%
$12.17
+468.8%
-93.6%$26.06M$1.16M-0.4339

Related Companies and Tools


This page (NASDAQ:APLM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners